Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
0.3097
-0.0022 (-0.71%)
At close: Apr 1, 2025, 4:00 PM
0.3093
-0.0004 (-0.15%)
After-hours: Apr 1, 2025, 4:16 PM EDT
Ovid Therapeutics Revenue
In the year 2024, Ovid Therapeutics had annual revenue of $566.00K with 44.39% growth. Ovid Therapeutics had revenue of $76.00K in the quarter ending December 31, 2024, a decrease of -46.48%.
Revenue (ttm)
$566.00K
Revenue Growth
+44.39%
P/S Ratio
39.08
Revenue / Employee
$24,609
Employees
23
Market Cap
22.01M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 566.00K | 174.00K | 44.39% |
Dec 31, 2023 | 392.00K | -1.11M | -73.91% |
Dec 31, 2022 | 1.50M | -206.88M | -99.28% |
Dec 31, 2021 | 208.38M | 195.77M | 1,551.57% |
Dec 31, 2020 | 12.62M | - | - |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
OVID News
- 21 days ago - Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 4 weeks ago - Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors - GlobeNewsWire
- 4 weeks ago - Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 7 weeks ago - Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 7 months ago - Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth - GlobeNewsWire
- 8 months ago - Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm - Accesswire
- 8 months ago - Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm - Accesswire
- 8 months ago - Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm - Accesswire